#United States #Austin #patient recruitment #SubjectWell #Clariness

Clariness and SubjectWell Merge to Form a Comprehensive Patient Recruitment Platform

In a significant move within the healthcare sector, Clariness and SubjectWell announced their merger to form a powerhouse in global patient recruitment services. This merger aims to leverage the strengths of both companies to create a full-service platform focused on accelerating clinical trial access and improving execution worldwide.

The deal comes on the heels of WindRose Health Investors' acquisition of SubjectWell in April 2024, showcasing the firm’s commitment to enhancing patient recruitment capabilities in clinical research. Both companies will continue as a unified organization under the Clariness brand, combining their existing technologies and resources.

Key Features of the New Entity

1. Global Patient Recruitment Leader

By merging, the newly formed Clariness platform stands as one of the largest global patient recruitment platforms. It boasts local teams with a profound understanding of cultural contexts, enabling it to support clinical trials in over 60 countries across North America, South America, Europe, and the Asia Pacific region.

2. Unmatched Expertise in Patient Recruitment

The merged organization brings a wealth of experience, having delivered over 42,000 randomizations and partnered with more than 10,000 research sites. With a robust database of patients and comprehensive marketing strategies, the company is poised to enhance recruitment results significantly. This integration not only promises to expedite clinical trial processes but also aims to provide strategic advantages to its clientele by offering best-in-class solutions.

3. Focus on Patient-Centered Solutions

By prioritizing a human-centered approach, Clariness aims to improve the patient experience throughout the clinical trial journey. The merger looks to leverage data and technology to drive faster enrollment, enhance predictability, and ensure stronger retention rates across the clinical trial lifecycle.

4. Leadership and Vision

Fred Martin, CEO of SubjectWell, emphasized the common vision shared by both organizations, which focuses on quality and customer service. He stated that this merger allows for greater scale, speed, and consistency, thereby improving patient access to clinical trials. Clariness CEO, Stefan Mayer-Eggersmann, expressed excitement about the potential to set new standards in patient recruitment metrics as the combined entity’s expertise is harnessed to improve efficiency and service delivery.

Industry Impact

The combination of Clariness and SubjectWell represents a strategic effort to address the pressing needs of clinical research through enhanced patient recruitment strategies. The increased scale and capabilities come at a time when healthcare companies are striving to accelerate drug development processes and improve overall patient access and participation in clinical trials. This merger is expected to significantly impact the healthcare sector, providing an avenue for more innovative and effective clinical research methodologies.

Conclusion

The collaboration between Clariness and SubjectWell not only symbolizes a step forward in patient recruitment but also sets the groundwork for future innovations within clinical research practices. As they work collectively to transform patient recruitment, this merger stands to benefit biopharma sponsors, Contract Research Organizations (CROs), and healthcare providers globally, ensuring a better, more patient-focused approach to clinical trials.

For more information about their services and offerings, visit Clariness and SubjectWell.